INTRODUCTION
Platelet transfusions are relatively common in neonatal intensive care units (NICUs). 1,2,4,5,7 -9 Some transfused neonates receive only a single transfusion, yet others receive multiple transfusions over a period of many weeks. For any given neonate about to receive a platelet transfusion, one cannot predict whether a single transfusion, or multiple transfusions, will be needed. In addition, little information contrasting the outcomes of neonates who receive no platelet transfusions, one transfusion, or multiple transfusions is available. Moreover, alternative treatments, such as recombinant thrombopoietin (rTpo) administration, have not been investigated in thrombocytopenic neonates.
In certain thrombocytopenic adult patients, rTpo appears to be an attractive alternative. 2,3,5,8 -10,19 In our in vitro studies 11 and in neonatal rhesus monkey experiments, 12 we showed that neonates are likely to respond favorably to rTpo administration. Not all severely thrombocytopenic NICU patients will be suitable candidates for treatment with rTpo. In some patients, the thrombocytopenia is short-lived. Our studies of rTpo administration to newborn rhesus monkeys, 12 and reports of others involving adult animals and humans 8 -10,12 indicate that rTpo will not elevate the platelet count until about 5 days after starting treatment. Therefore, the only thrombocytopenic NICU patients who are likely to benefit from rTpo are those who would require multiple platelet transfusions over a period of more than 5 days. The intent of the current study is to determine whether demographic, laboratory, or clinical features may prospectively identify those thrombocytopenic NICU patients who will require multiple platelet transfusions over a period of more than 5 days.
In the USA, local and regional differences exist in platelet transfusion practices. 13 However, no information is available from Mexico regarding neonatal platelet transfusion practices, or outcomes of neonatal transfusion recipients, nor have studies been done to identify groups of neonatal patients in Mexico that might be reasonable candidates for rTpo trials. To obtain some of this information, we performed a historic cohort analysis of patients in the Neonatology Units of the National Institute of Perinatology (Mexico City, Mexico) during the period 1997 to 2000. This study had four aims: (1) to obtain descriptive information regarding platelet transfusions in this unit; (2) to test demographic and laboratory factors that would predict which patients would receive single and which would receive multiple platelet transfusions; (3) to determine the association of platelet transfusions with outcomes; and (4) to test epidemiological factors that would predict ''good candidates'' for rTpo administration. ''Good candidates'' were defined as thrombocy-
We conducted a historic cohort study of neonates who received platelet transfusions at the National Institute of Perinatology, Mexico City, from January 1997 to May 2000. We obtained descriptive and outcome data, and assessed demographic and laboratory means of predicting ''good candidates'' for a future recombinant thrombopoietin ( rTpo ) trial.
RESULTS:
A minority of the transfused patients ( 11.4% ) received only one transfusion; the majority ( 88.6% ) received multiple transfusions. Neonates who received one or more platelet transfusions were more likely to die ( 24.5% mortality ) than neonates who received no platelet transfusions ( 3.7% mortality ) . Regression analyses indicated that the presence of liver disease was the best predictor of a ''good candidate'' for rTpo administration.
CONCLUSION:
The majority of neonates in our institution who receive platelet transfusions receive multiple, not single, transfusions. Receiving any platelet transfusion is a marker for high risk of death. Neonates with liver disease who receive platelet transfusions might be a reasonable group for a phase I rTpo trial. 
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topenic neonates who received multiple platelet transfusions spanning a period of 5 days or more.
METHODS

Subjects and Data Collection
We began by reviewing the Blood Bank records of the National Institute of Perinatology from January 1, 1997 to May 31, 2000 in order to identify neonates who received one or more platelet transfusions. We next obtained the medical records of the transfused neonates, and recorded pre-determined demographic, laboratory, and outcome data on data coding sheets. The admission data included demographic information (gender, gestational age, birthweight), labor and delivery complications (meconium-stained fluid, fetal distress, placental abruption, and so on), Apgar scores, and admission diagnosis. The maternal data included maternal age, medications, pregnancy complications (such as pregnancy-induced hypertension or chorioamnionitis), maternal autoimmune diseases, and history of documented viral infections. The transfusion factors included information about the clinical condition of the infant at the time of the first platelet transfusion. Variables included complete blood counts and coagulation tests at the time of the first transfusion. Information regarding the clinical condition of the neonate during that period was also recorded, including clinical diagnosis (such as infections, necrotizing enterocolitis, disseminated intravascular coagulation, liver disease, renal failure, and so on), presence of central lines, respiratory assistance, and medications. Any indication of clinical bleeding was also recorded. We considered patients with liver disease who, at the time of the first platelet transfusion, had alanine aminotransferase greater than two times the upper limit of normal and/or direct hyperbilirubinemia (defined as direct bilirubin >2 mg/dl or >20% of the total bilirubin if there was evidence of hemolysis). Patients with oliguria ( <1 ml/kg per hour), serum creatinine >1.5 mg/dl, and BUN >20 mg/dl were categorized as having renal insufficiency. DIC was defined as a platelet count <150,000/l, a prolonged PT and aPTT, and elevated D-dimers.
Platelet Transfusions Criteria
The National Institute of Perinatology had established criteria for platelet transfusion -platelet count of <20,000/l or platelet count of <50,000/l with active bleeding. 14 
Outcomes
Outcome was categorized as either survival to transfer or discharge or death. We defined resolution of thrombocytopenia as a platelet 
Statistical Analysis
Descriptive and demographic factors were expressed as mean and SD. In addition, we performed one-way analysis of variance to test for differences between three groups. Contingency tables and Fisher's exact test were employed to test associations between the binary response variables by transfusion group. Differences were considered significant at p 0.05. The relative risk of death as a function of the number of the time-dependent covariate platelet transfusions was modeled using Cox's proportional hazards model. In the analysis that attempted to identify ''good candidates'' for a rTpo trial, the following two criteria were applied: (1) the patient had to have survived at least 5 days from the time of the first platelet transfusion (because patients who die quickly would not be good candidates), and (2) the patient had to have received more than one platelet transfusion, with at least one transfusion being given 5 days or more after the first (because rTpo administration requires at least 5 days to effectuate an increase in blood platelet count 12 ). We carried out univariate logistic regression analyses on each of over 100 possible predictors of these two outcomes. A subset of the 10 best predictors (based on their likelihood ratio values) was chosen to be included in a stepwise regression model, from which the final model was determined. All statistical analyses were performed using SAS 6.12 (SAS Institute, Cary, NC).
RESULTS
A total of 6551 patients were admitted to the neonatal care units at the National Institute of Perinatology during the designated period. Of these, 136 (2%) received one or more platelet transfusions. Sixtythree of 136 medical records (46.3%) were missing and 12 (8.8%) were too incomplete to allow study. Therefore, a total of 61 records, representing 44.8% of all transfused neonates, formed the basis of the study. Of these 61, 7 (11.5%) received only one platelet transfusion, whereas 54 (88.5%) received more than one (Figure 1 ). The platelet count at which the first platelet transfusion was ordered ranged from 1000/l to >100,000/l, and is displayed in Figure 2 .
Certain demographic features, laboratories tests, and clinical diagnoses of the patients who received one transfusion were contrasted with those who received two to four transfusions, and those who received more than four transfusions (representative categories showed in the Table 1 ). None of the demographic features, laboratory tests, or clinical diagnoses accurately predicted patients who would receive one, two to four, or more than four platelet transfusions. The 18 patients with liver disease had a trend toward receiving multiple, rather than single, platelet transfusions (p=0.07).
The group of seven patients who received only one platelet transfusion was heterogeneously composed of patients who did not need more transfusions and those who died before being able to receive more transfusions. In fact, three of these seven died, and all died rapidly. These three were all premature (24, 27, and 28 weeks' gestation), all had intraventricular hemorrhage, and all were receiving mechanical ventilation. Since rTpo treatment would only benefit neonates who are alive and still thrombocytopenic 5 days after the first platelet transfusion, we performed regression analysis to predict this outcome. As shown in Table 2 , the presence of liver disease was the only predictive element. The odds of being alive and still requiring platelet transfusions 5 days after the first transfusion was 8.1 times higher in the presence of liver disease than in its absence (p=0.001). No other variables contributed additional information toward the final model fit.
Most of the patients with liver disease did not have a primary hepatic disorder, but rather had liver dysfunction as consequence of a systemic insult. Three had severe birth asphyxia, 7 had severe intrauterine growth retardation, 11 had confirmed sepsis, and 2 had meningitis.
The mortality rate of those patients who received one or more platelet transfusions was 24.5%, compared with an overall mortality rate of 3.7% among patients in our NICU during this period. There were no differences in the relative risk of death as a function of the number of platelet transfusions received. The clinical diagnoses of the 15 non-survivors were: intraventricular hemorrhage (nine), confirmed sepsis (five), and liver disease (four).
The mortality rate of the 63 patients who were excluded from the analysis because of missing or incomplete medical records was 25.4% (16/63), which was the same mortality rate as those with complete records (24.5%). Also, the number of platelet transfusions received was similar among the group of 16 patients who died but were excluded from the analysis because of missing or incomplete records and the 15 who died and had complete records; 12.5% received one platelet transfusion, 37.5% received two to four, and 50% received more than four transfusions. 
DISCUSSION
Thrombocytopenia, defined as a platelet count of <150,000/l, is a very common hematological abnormality in the neonatal period, 4, 10 affecting up to 35% of all infants admitted to the NICU. 2, 8 Many fetomaternal and neonatal conditions are known to be associated with fetal and neonatal thrombocytopenia; these include infections, hypoxia, low birthweight, disseminated intravascular coagulation, pregnancy-induced hypertension, and chromosomal and congenital abnormalities. 4, 15 The majority of cases of thrombocytopenia in the NICU occur in premature infants. 1 -3,10 Thirty-five to forty percent of thrombocytopenic neonates have a platelet count below 100,000/l, and 15% to 20% have counts below 50,000/l. 2 The only treatment currently available for these patients is the administration of platelet transfusions, except in cases of immune-mediated neonatal thrombocytopenia where IVIG and steroids have been shown to be useful. 1, 3, 4, 6, 15 Despite marked advances in procedures for ensuring the safety of platelet transfusions, including intensive donor screening, infectious disease marker testing, and increased use of leukodepletion techniques, platelet transfusions still carry risks and are expensive. 16 Tpo is the recently discovered physiologic regulator of platelet production, and rTpo appears to be a reasonable alternative to platelet transfusions in certain groups of thrombocytopenic adults. 17 Given the frequent occurrence of thrombocytopenia among NICU patients, the idea of using, as an alternative to multiple platelet transfusions, rTpo to treat thrombocytopenic neonates is appealing. 22 However, our animal studies using newborn rhesus monkeys have shown that it takes 5 days from the start of rTpo therapy before a rise in the platelet count is first detected. 2, 9, 12 Thus, the only thrombocytopenic neonates likely to benefit from rTpo treatment are those who receive multiple platelet transfusions spanning a period of 5 days or more.
The present study was done to better define the group of thrombocytopenic NICU patients who require multiple platelet transfusions over 5 days or more, and would therefore be reasonable candidates for a Phase I rTpo trial. Our results suggest that demographic features cannot be used as factors to predict the duration or severity of the thrombocytopenia among NICU patients. However, liver disease was predictive of the need for multiple platelet transfusions over a period of more than 5 days. The mechanism whereby liver disease produces thrombocytopenia is not clearly understood, but studies in adults with this condition suggest that decreased Tpo production, leading to decreased thrombopoiesis, might be the primary mechanism. 2 -4,5,8,18 This theory is supported by the fact that the liver is the principal Tpo-producing organ in neonates and adults 17, 22 and that Tpo mRNA expression is diminished in the liver of pediatric patients with cirrhosis and acute liver failure. 20 Similar to our observation in neonates, a recent analysis of risk factors for thrombocytopenia among adult intensive care patients showed a strong correlation between severe thrombocytopenia and liver function abnormalities. 23 The percentage of our patients who received platelet transfusions (2%) was lower than has been reported from other centers, such as Florida (9.4%, Sola et al.) and Canada (7.4%, Andrews et al. 19 ). Perhaps this is the result of basic differences in patients mix. Specifically, perhaps the relatively low usage of platelet transfusions among our patients is due to our very large intermediate care facility (45 beds) with a relatively small intensive care unit (16 beds), whereas the units reporting a high incidence of platelet transfusions have a large percentage of intensive care patients. Indeed, thrombocytopenia is more common in populations of neonates who are more ill. 6, 9, 21 Regardless of the patient mix, our study shows that NICU patients who receive platelet transfusions have a poor outcome. The fact that this group has a high mortality rate must also be considered when designing and analyzing the first rTpo trial in the NICU.
